As the second quarter earnings crunch begins in earnest this week, the bear market has investors jittery and prognosticators spinning out dire warnings. In the wake of mixed results from Alcoa (NYSE: AA) and General Electric (NYSE: GE) kicking things off last week, here's a look at what Wall Street is expecting from many of the companies scheduled to report this coming week.

Analysts surveyed by Thomson Financial are expecting the following companies to report a rise in earnings when compared to the same period of the previous year.

• Nucor Corp. (NYSE: NUE): $1.80 EPS (36.6%) on sales of $6.4 billion (+53.0%)
• Google Inc. (NASDAQ: GOOG): $4.74 EPS (24.9%) on sales of $3.9 billion (+41.6%)
• Nokia Corp. (NYSE: NOK): 56 cents EPS (23.2%) on sales of $19.9 billion (+17.8%)
• CSX Corp. (NYSE: CSX): 90 cents EPS (21.1%) on sales of $2.9 billion (+12.8%)
• Altera Corp. (NASDAQ: ALTR): 27 cents EPS (18.5%) on sales of $346.7 million (+8.4%)
• IBM (NYSE: IBM): $1.82 EPS (+17.6%) on sales of $25.9 billion (+9.0%)
• eBay Inc. (NASDAQ: EBAY): 41 cents EPS (17.1%) on sales of $2.2 billion (+18.0%)
• W.W. Grainger Inc. (NYSE: GWW): $1.46 EPS (17.1%) on sales of $1.7 billion (+8.0%)
• Microsoft Corp. (NASDAQ: MSFT): 47 cents EPS (17.0%) on sales of $15.7 billion (+17.0%)
• Honeywell International Inc. (NYSE: HON): 94 cents EPS (17.0%) on sales of $9.2 billion (+7.9%)

MAJOR PAPERS:

• This year, the International Trade Commission is set to issue rulings on whether Samsung and Nokia Corporation (NYSE: NOK) have infringed patents from InterDigital Inc (NASDAQ: IDCC). If InterDigital, who licenses its patents to iPhone maker Apple Inc (NASDAQ: AAPL), wins, fees from the deals could double its revenue over the next few years, the Wall Street Journal contended.
• The Wall Street Journal also reported that Macy's Inc (NYSE: M) is among the retailers that include The Home Depot Inc (NYSE: HD) and Sears Holdings Corporation (NASDAQ: SHLD) to stop making its monthly disclosure of retail sales.

OTHER PAPERS:

• According to FDA commissioners, the New York Times reported that Baxter International Inc's (NYSE: BAX) critical blood thinner heparin, which has been linked to nearly 20 deaths and whose base was created in China, contained a "possibly counterfeit" ingredient that "mimicked the real drug."
• In his opening arguments in the state of Alaska's lawsuit against Eli Lilly & Company (NYSE: LLY), an attorney for the state alleged the drug maker failed to warn doctors and patients of dangerous side effects associated with its drug Zyprexa, the Associated Press reported.

I'm always troubled when I see financial pundits offering investors "stock tips" that consist of little more than a look at a chart, a summary of analyst opinion, and some ratios pulled off of Yahoo! Finance. None of these really help investors answer the question: "How does this company make money?" The notion that anyone should invest in a stock without being able to answer that question in great detail is not one that I subscribe to.

In recent weeks, 2 of my favorite financial journalists -- MarketWatch's Herb Greenberg and Fortune's Roddy Boyd -- looked at companies where a large chunk of the earnings come from venues very different from what is thought to be the core business.

First, Herb Greenberg wrote about Whirlpool Corporation (NYSE: WHR). You thought they made money selling appliances and such, right? Well there's that but 26% of the company's fourth quarter profits came from Brazilian tax credits. There's nothing inherently wrong with that -- but realize that if you're going to invest in shares of WHR, you need to look at not just the future of the appliance industry but also the future of those tax credits.

MOST NOTEWORTHY: Amag Pharmaceuticals, Corn Products and Alpharma were today's noteworthy initiations:

• Baird initiated Amag Pharmaceuticals (NASDAQ: AMAG) with an Outperform rating and believes concerns regarding ferumoxytol approvability are misplaced.
• JP Morgan assumed coverage of Corn Products (NYSE: CPO) with an Overweight rating and points to the company's growth in emerging markets and improved business economics in its core U.S. market.
• RBC Capital is positive on Alpharma's (NYSE: ALO) Flector opportunity in the U.S. topical NSAID market. The firm started shares with an Outperform rating and $28 target.

OTHER INITIATIONS:

• Merrill resumed coverage of Baxter (NYSE: BAX) with a Buy rating.
• Goldman initiated Teradyne (NYSE: TER) with a Neutral rating and $11 target.
• Allianz AG (NYSE: AZ) was initiated with a Buy rating at Societe Generale.

Goldman Sachs has made several changes to its Conviction Buy List this morning. Most notably was a removal of Wal-Mart Stores Inc. (NYSE:WMT) from the list. Goldman replaced Wal-Mart's place with Target Corp. (NYSE:TGT).

TGT was given a $68 target and WMT target was cut to $53 from $57 per share. On Wal-Mart, Goldman analysts believe a turnaround is in its early stages and they see little positive momentum into the critical holiday season. Goldman Sachs maintained an official Buy rating for WMT, but simultaneously lowered Fiscal 2006 EPS from $2.87 to $2.83. Target (TGT) EPS estimates were raised by $0.01 to $3.18.

Baxter International Inc. (NYSE:BAX) & Aracruz Celulose (NYSE:ARA) were also trimmed off the Americas Conviction Buy List as was Flextronics International Ltd. (NASDAQ:FLEX). FLEX shares are down 9% since being added to the list in September and Goldman expects a more of a seasonal slowdown. On the other hand, Crown Holdings (NYSE:CCK) was added to Goldman Sachs Americas Conviction Buy List.

Jon Ogg is a partner in 24/7 Wall St., LLC; he does not own securities in the companies he covers.